The incretin/glucagon system as a target for pharmacotherapy of obesity

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

(2021) Rajaa Nahra et al.   DIABETES CARE

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

(2021) Bernhard Ludvik et al.   LANCET

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

(2020) Natasha C. Bergmann et al.   DIABETES CARE

GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

(2020) Lærke S Gasbjerg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis

(2020) Aimo Kannt et al.   DIABETES OBESITY & METABOLISM

GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists

(2020) Jens Juul Holst et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

(2020) David M. Williams et al.   Diabetes Therapy

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

(2020) Ricardo J. Samms et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Long-acting GLP-1RAs

(2020) Ji Hyun Chun et al.   JAAPA-Journal of the American Academy of Physician Assistants

Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide ( GIP) receptor antagonist GIP (3‐30) NH 2 on GIP actions in humans

(2020) Lærke Smidt Gasbjerg et al.   DIABETES OBESITY & METABOLISM

Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

(2020) Marie Winther-Sørensen et al.   Molecular Metabolism

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals

(2019) Lærke S. Gasbjerg et al.   DIABETES

Non-conventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP

(2019) Oleg G. Chepurny et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy

(2019) Maria S. Svane et al.   GASTROENTEROLOGY

The liver-alpha cell axis and type 2 diabetes

(2019) Nicolai J Wewer Albrechtsen et al.   ENDOCRINE REVIEWS

Glucagon Receptor Signaling and Lipid Metabolism

(2019) Katrine D. Galsgaard et al.   Frontiers in Physiology

990-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model

(2019) JUNG KUK KIM et al.   DIABETES

A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial

(2019) Mads J. Skytte et al.   DIABETOLOGIA

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

(2019) Alice E. Adriaenssens et al.   Cell Metabolism

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review

(2019) David S. Mathiesen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Obesity dysregulates fasting-induced changes in glucagon secretion

(2019) Jennifer H Stern et al.   JOURNAL OF ENDOCRINOLOGY

Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates

(2019) Patrick J. Knerr et al.   PEPTIDES

Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later?

(2019) Andrea G. Izquierdo et al.   Nutrients

Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes

(2019) Maria J. Pereira et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs

(2019) Awadhesh Kumar Singh et al.   Expert Review of Clinical Pharmacology

Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates

(2018) Ralf Elvert et al.   DIABETES OBESITY & METABOLISM

Incretin hormones: Their role in health and disease

(2018) Michael A. Nauck et al.   DIABETES OBESITY & METABOLISM

Centrally Acting Agents for Obesity: Past, Present, and Future

(2018) Ann A. Coulter et al.   DRUGS

Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes

(2018) Megan E Capozzi et al.   ENDOCRINE REVIEWS

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

Prevalence and Determinants of Engagement with Obesity Care in the United States

(2018) Andrew Stokes et al.   Obesity

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss

(2018) Jens Juul Holst et al.   Surgery for Obesity and Related Diseases

Regulation of amino acid metabolism and α-cell proliferation by glucagon

(2018) Yoshitaka Hayashi et al.   Journal of Diabetes Investigation

Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity

(2018) Sadiya S. Khan et al.   JAMA Cardiology

Non-alcoholic fatty liver disease – A global public health perspective

(2018) Zobair M. Younossi   JOURNAL OF HEPATOLOGY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases

(2018) Christoffer Clemmensen et al.   Nature Reviews Endocrinology

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

(2018) Elizabeth A. Killion et al.   Science Translational Medicine

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

(2018) Piotr A. Mroz et al.   Molecular Metabolism

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

(2017) Carel W le Roux et al.   LANCET

Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation

(2017) G.A. Bray et al.   Obesity Reviews

Obesity

(2017) Pedro González-Muniesa et al.   Nature Reviews Disease Primers

Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes

(2016) Nicolai J. Wewer Albrechtsen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review

(2016) Igho J. Onakpoya et al.   BMC Medicine

Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus

(2016) Eric G. Vajda et al.   DIABETES OBESITY & METABOLISM

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

(2016) W. Timothy Garvey et al.   Endocrine Practice

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

(2016) M S Svane et al.   INTERNATIONAL JOURNAL OF OBESITY

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations

(2016) Francesco Rubino et al.   OBESITY SURGERY

Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations

(2015) Tine M. Frederiksen et al.   BIOPHYSICAL JOURNAL

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

(2015) V. Salem et al.   DIABETES OBESITY & METABOLISM

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

(2015) Jonatan Ising Bagger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

(2015) Caroline M. Apovian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Islet α cells and glucagon—critical regulators of energy homeostasis

(2015) Jonathan E. Campbell et al.   Nature Reviews Endocrinology

European Guidelines for Obesity Management in Adults

(2015) Volkan Yumuk et al.   Obesity Facts

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

(2015) Darleen A. Sandoval et al.   PHYSIOLOGICAL REVIEWS

Distribution of glucagon-like peptide 1-immunopositive neurons in human caudal medulla

(2014) Huiyuan Zheng et al.   Brain Structure & Function

Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

(2014) Jaimini Cegla et al.   DIABETES

Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue

(2014) Keita Kinoshita et al.   ENDOCRINOLOGY

Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1

(2014) David P Sonne et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

(2014) Anna Secher et al.   JOURNAL OF CLINICAL INVESTIGATION

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Effects of GLP-1 on appetite and weight

(2014) Meera Shah et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala

(2013) J A Parker et al.   INTERNATIONAL JOURNAL OF OBESITY

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Hypothalamic glucagon signaling inhibits hepatic glucose production

(2013) Patricia I Mighiu et al.   NATURE MEDICINE

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

(2012) Jonathan W. Day et al.   BIOPOLYMERS

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

(2012) T. M. Tan et al.   DIABETES

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

(2011) F. K. Knop et al.   DIABETES OBESITY & METABOLISM

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Effects of central administration of glucagon on feed intake and endocrine responses in sheep

(2009) Yohei KUROSE et al.   ANIMAL SCIENCE JOURNAL

The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

(2009) Daphne P Guh et al.   BMC PUBLIC HEALTH

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet

(2008) Iris Shai et al.   NEW ENGLAND JOURNAL OF MEDICINE